Jackson Melissa A, Brown Amanda L, Baker Amanda L, Bonevski Billie, Haber Paul, Bonomo Yvonne, Blandthorn Julie, Attia John, Perry Natasha, Barker Daniel, Gould Gillian S, Dunlop Adrian J
Hunter New England Health Local Health District, Newcastle, NSW, Australia.
School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
Front Psychiatry. 2023 Aug 16;14:1207955. doi: 10.3389/fpsyt.2023.1207955. eCollection 2023.
Most pregnant women with substance use problems smoke, and few will quit during their pregnancy. Tobacco treatment is often overlooked, with the focus usually placed on other substance use. Additionally, few targeted effective treatments for this group exist. To address this, the feasibility of an intensive tobacco treatment incorporating contingency management (CM) that featured non-face-to-face delivery was examined.
A single-arm pre-post design feasibility trial was conducted in three antenatal services that support women who use substances in metropolitan Australia. Participants were over the age of 15, had <33-week gestation, and smoked tobacco daily. They received financial incentives for daily carbon monoxide-verified smoking abstinence or reduction through an internet-based CM programme, nicotine replacement therapy (NRT) posted to women and partners or household members who smoked and telephone-delivered behavioral counseling from study enrolment to birth.
Of the 101 referrals, 46 women (46%) consented. The mean (SD) age was 31(±6) years, and the gestation period was 22(±6) weeks. Nineteen (41%) of those enrolled were retained for 12-week postpartum. Of 46 women, 32 (70%) utilized CM; 32 (70%) used NRT for ≥2 weeks; 23 (50%) attended ≥1 counseling session; and 15 (22%) received NRT for partners/household members. Fifteen (33%) were verified abstinent from tobacco at delivery after a median (IQR) period of abstinence of 65(36-128) days. All non-smokers at birth utilized NRT and financial incentives, and 9/15 (60%) utilized counseling. Four (9%) were abstinent at 12-week postpartum. Median cigarettes smoked/day reduced from baseline to delivery (10(6-20) to 1(0-6) p =< 0.001). Women who quit smoking had more education (72% vs. 33% p =< 0.02), completed more CO samples (median (IQR) 101(59-157) vs. 2(0-20) p =< 0.001), and received more incentives (median (IQR) $909($225-$1980) vs. $34($3-$64) p =< 0.001). Intervention acceptability was rated favorably by participants (9 items rated 0-10 with scores >5 considered favorable).
This study demonstrated the feasibility and acceptability of a consumer-informed, non-face-to-face intensive tobacco treatment, highlighting the potential of remotely delivered technology-based CM to reduce the health impact of tobacco smoking in high-priority populations. The intervention demonstrates scale-up potential. Future studies should extend treatment into the postpartum period, utilizing new technologies to enhance CM delivery and improve counseling provision and partner support.
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374196, ACTRN1261800056224.
大多数有药物使用问题的孕妇吸烟,且很少有人会在孕期戒烟。烟草治疗常常被忽视,重点通常放在其他药物使用上。此外,针对这一群体的有效靶向治疗方法很少。为解决这一问题,我们考察了一种采用应急管理(CM)的强化烟草治疗的可行性,该治疗采用非面对面的方式进行。
在澳大利亚大都市地区的三个产前服务机构开展了一项单组前后设计的可行性试验,这些机构为使用药物的女性提供支持。参与者年龄超过15岁,妊娠<33周,且每天吸烟。通过基于互联网的CM项目,她们因每日经一氧化碳验证的戒烟或减少吸烟量而获得经济激励,尼古丁替代疗法(NRT)会邮寄给吸烟的女性及其伴侣或家庭成员,并且从研究入组到分娩期间会通过电话提供行为咨询。
在101名被转诊者中,46名女性(46%)同意参与。平均(标准差)年龄为31(±6)岁,妊娠期为22(±6)周。其中19名(41%)入组者在产后12周仍被随访。在46名女性中,32名(70%)采用了CM;32名(70%)使用NRT≥2周;23名(50%)参加了≥1次咨询;15名(22%)为伴侣/家庭成员领取了NRT。在中位(四分位间距)65(36 - 128)天的戒烟期后,15名(33%)在分娩时被验证为戒烟。所有出生时不吸烟的人都使用了NRT和经济激励,15名中的9名(60%)使用了咨询。4名(9%)在产后12周时仍为戒烟状态。从基线到分娩,每日吸烟支数中位数从10(6 - 20)降至1(0 - 6)(p =< 0.001)。戒烟的女性受教育程度更高(72%对33%,p =< 0.02),完成的一氧化碳样本更多(中位(四分位间距)为101(59 - 157)对2(0 - 20),p =< 0.001),获得的激励更多(中位(四分位间距)为909美元(225 - 1980美元)对34美元(3 - 64美元),p =< 0.001)。参与者对干预措施的可接受性评价良好(9项指标评分0 - 10分,得分>5分被认为是良好)。
本研究证明了一种以消费者为导向的、非面对面的强化烟草治疗的可行性和可接受性,突出了基于远程技术的CM在减少高危人群吸烟对健康影响方面的潜力。该干预措施显示出扩大规模的潜力。未来的研究应将治疗扩展到产后阶段,利用新技术加强CM的实施,并改善咨询服务和伴侣支持。
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374196,ACTRN1261800056224。